FDA Inspection 965700 — Novacyl Wuxi Pharmaceutical Co., Ltd.
The FDA completed an inspection of Novacyl Wuxi Pharmaceutical Co., Ltd. on April 14, 2016 in Wuxi. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- April 14, 2016
- Fiscal Year
- 2016
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuxi (China)